Voriconazole
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
- Invasive aspergillosis
- Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
- Esophageal candidiasis
- Candidemia in non-neutropenic patients and other deep tissue Candida infections
NON-FDA APPROVED USES
- Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
- Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Voriconazole is FDA approved for the following indications in adults and pediatrics ≥ 2 years of age:
- Invasive aspergillosis
- Serious infections caused by Scedosporium apiospermum (Pseudallescheria boydii) and Fusarium spp. (including F. solani) in patients intolerant of, or refractory to, other therapies.
- Esophageal candidiasis
- Candidemia in non-neutropenic patients and other deep tissue Candida infections
NON-FDA APPROVED USES
- Prophylaxis of invasive aspergillosis and disseminated candidiasis in severely immunocompromised hosts
- Based on in-vitro data and limited clinical experience, voriconazole may be effective for infections due to certain dematiaceous fungi (C. immitis)
There's more to see -- the rest of this topic is available only to subscribers.